US market expansion Caristo is planning a commercial launch of CaRi-Heart in the United States in Q3 2026 with further expansion in Q4 2026, representing a direct sales opportunity to engage hospital systems, radiology groups, and cardiovascular centers looking to adopt AI-driven cardiac imaging tools.

Executive leadership Recent appointments of a Chief Commercial Officer and a Chief Financial Officer signal a focus on scaling globally and accelerating adoption; leverage these leaders to align enterprise sales motions, channel partnerships, and financial justification for customers.

Clinical validation New evidence and research presentations around non-contrast cardiac CT, stroke prediction, and virtual biopsy data at ESC Congress and SCCT meetings provide compelling clinical talking points to support procurement discussions with cardiology and radiology departments.

AI cardiovascular focus Caristo’s AI-powered cardiovascular diagnostics offer enhanced accuracy on routine CT scans, providing a differentiator for health systems seeking precision risk stratification and refined treatment decisions, which can drive reimbursement and value-based care conversations.

Funding and scale readiness With $30M in funding and revenue in the low millions, Caristo appears financially positioned to invest in enterprise pilots, training, and deployment scale; engage healthcare networks with pilot programs, ROIs, and total cost of ownership analyses to accelerate signings.